Santosh Kesari, MD, PhD joins The Lundquist Institute as an esteemed investigator in Cancer Biology and Immunotherapeutics, bringing exceptional expertise as a board-certified neurologist, oncologist, and clinical trialist.
His multidisciplinary research spans autoimmunity, cancer, and neuroscience, with a long-standing commitment to advancing precision therapeutic strategies against difficult-to-treat malignancies. His work encompasses targeted therapies, chemotherapy, immunotherapy, radiation therapyand novel devices—all with the goal of transforming scientific discovery into impactful clinical solutions.
Dr. Kesari’s career reflects a remarkable blend of clinical excellence and translational research. Located in the Hanley-Hardison Research Center at The Lundquist Institute, The Kesari Lab is focused on precision and translational medicine for rare and aggressive cancers, including efforts to overcome treatment resistance and understand tumor–immune interactions. From mechanistic discovery to patient-centered therapies, the lab embodies our institute’s mission to translate knowledge into real-world impact.
“I’m excited to be a part of The Lundquist Institute,” said Dr. Kesari. “I look forward to developing new therapies for patients with rare or high-unmet diseases including highly resistant cancers, neurodegeneration and autoimmune diseases.”
Please join us in extending a warm welcome to Dr. Kesari. We look forward to the many scientific advances and collaborative opportunities his leadership will bring.